Robert Fried N.'s most recent trade in Niagen Bioscience Inc. was a trade of 66,667 Stock Options (right to buy) done . Disclosure was reported to the exchange on April 9, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Niagen Bioscience Inc. | Robert N. Fried | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Apr 2025 | 66,667 | 0 | - | - | Stock Options (right to buy) | |
| Niagen Bioscience Inc. | Robert N. Fried | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.30 per share. | 09 Apr 2025 | 66,667 | 1,038,981 (1%) | 0% | 3.3 | 220,001 | Common Stock |
| Niagen Bioscience Inc. | Robert N. Fried | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2025 | 1,518,600 | 1,518,600 | - | - | Performance Stock Unit | |
| Niagen Bioscience Inc. | Robert N. Fried | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 492,278 | 492,278 | - | - | Employee Stock Options (right to buy) | |
| Niagen Bioscience Inc. | Robert Fried N. | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2024 | 399,568 | 399,568 | - | - | Employee Stock Options (right to buy) | |
| Niagen Bioscience Inc. | Robert N. Fried | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 1.42 per share. | 31 May 2023 | 7,000 | 95,001 (0%) | 0% | 1.4 | 9,940 | Common Stock |
| Niagen Bioscience Inc. | Robert N. Fried | Director, Cheif Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 306,366 | 306,366 | - | - | Employee Stock Options (right to buy) | |
| Niagen Bioscience Inc. | Robert N. Fried | Director, Cheif Executive Officer | Purchase of securities on an exchange or from another person at price $ 1.25 per share. | 30 Sep 2022 | 80,000 | 972,314 (1%) | 0% | 1.3 | 100,000 | Common Stock |
| Niagen Bioscience Inc. | Robert N. Fried | Director, CEO | Purchase of securities on an exchange or from another person at price $ 2.16 per share. | 16 Mar 2022 | 25,000 | 88,001 (0%) | 0% | 2.2 | 54,000 | Common Stock |
| Niagen Bioscience Inc. | Robert N. Fried | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2022 | 240,448 | 240,448 | - | - | Employee Stock Options (right to buy) | |
| Niagen Bioscience Inc. | Robert N. Fried | Director, CEO | Purchase of securities on an exchange or from another person at price $ 6.65 per share. | 13 May 2021 | 10,000 | 63,001 (0%) | 0% | 6.7 | 66,500 | Common Stock |
| Niagen Bioscience Inc. | Robert N. Fried | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2021 | 55,921 | 55,921 | - | - | Employee Stock Options (right to buy) |